Peregrine Pharmaceuticals (PPHM) Earnings: An Early Look – Celgene Corporation (CELG)

Earnings season is winding down, with most companies already having reported their quarterly results. But there are still some companies left to report, and Peregrine Pharmaceuticals (NASDAQ:PPHM) is about to release its quarterly earnings. The key to making smart investment decisions with stocks releasing their quarterly reports is to anticipate how they’ll do before they announce results, leaving you fully prepared to respond quickly to whatever inevitable surprises arise. That way, you’ll be less likely to make an uninformed knee-jerk reaction to news that turns out to be exactly the wrong move.

Peregrine Pharmaceuticals (NASDAQ:PPHM)Peregrine Pharmaceuticals (NASDAQ:PPHM) is one of many small biotech companies still looking to get their first drugs approved. Despite having very little in the way of revenue, the company has had a lot happening with it lately. Let’s take an early look at what’s been happening with Peregrine Pharmaceuticals (NASDAQ:PPHM) over the past quarter and what we’re likely to see in its quarterly report on Tuesday.

Stats on Peregrine Pharmaceuticals

Analyst EPS Estimate ($0.07)
Year-Ago EPS ($0.13)
Revenue Estimate $3.9 million
Change From Year-Ago Revenue 19%
Earnings Beats in Past 4 Quarters 3

Source: Yahoo! Finance.

What’s been happening with Peregrine Pharmaceuticals this quarter?
Analysts have raised their estimates slightly on Peregrine Pharmaceuticals (NASDAQ:PPHM) over the past few months, reducing their loss expectations by a penny per share for the just-ended quarter and by $0.03 per share for the full 2013 fiscal year. The stock has reflected even more optimism, rising nearly 30% since early December, but having given back much bigger gains from earlier this year.

Lately, investors have been on a roller-coaster ride with Peregrine Pharmaceuticals (NASDAQ:PPHM)’s stock. Last September, the company said that its own favorable clinical trial results for its most promising pipeline cancer drug, bavituximab, weren’t trustworthy, sending the shares down 80%. Yet by November, investors were getting more confident about the stock, seeing that mistakes made in the trial didn’t necessarily mean the drug didn’t work.

Then, in January, Peregrine said its third-party vendor had only mixed up part of its trial data, drawing favorable conclusions from the accurate part of the trial. Yet without explicit statistical analysis of the results, it’s hard for investors to compare bavituximab’s effectiveness against Celgene Corporation (NASDAQ:CELG)‘s rival pancreatic-cancer drug Abraxane.

In its earnings report, Peregrine Pharmaceuticals (NASDAQ:PPHM) needs to be as forthcoming about the bavituximab trial, providing as much statistical analysis as possible to help support its assertions that the drug has good prospects. Without that, it’s hard to see investors regaining confidence in the stock over the long haul.

The article Peregrine Pharmaceuticals Earnings: An Early Look originally appeared on Fool.com and is written by Dan Caplinger.

Fool contributor Dan Caplinger has no position in any stocks mentioned. You can follow him on Twitter: @DanCaplinger. The Motley Fool has no position in any of the stocks mentioned.

Copyright © 1995 – 2013 The Motley Fool, LLC. All rights reserved. The Motley Fool has a disclosure policy.

Comments
Insider Monkey Small Cap Strategy
Insider Monkey Small Cap Strategy

Insider Monkey beat the market by 52 percentage points in 24 months. Our beta is only 1.2 (don't click this link if beating the market isn't important to you).

Lists

The Best B-Boy Movies

Most Awesome Hip Hop Documentaries

Foods That Stain Your Teeth

Richest Doctors in the World

The Best Movie Sountracks Ever

The Highest Grossing Musicals on Broadway

The Most Successful Reality TV Stars

Cheapest Cities to Visit in the US

Most Expensive Summer Camps

Most Expensive Animals in the World

Most Expensive Specialty Crops in the World

Movies That Took Ages to Make

The Longest Hollywood Films Ever Made

Most Expensive Concert Stages

The Richest Bands of all Time

10 Most Corrupt Countries 2013 List

10 Countries with the Highest Quality of Life Index

Most Expensive Mattresses in the World

5 Smallest Countries by Land Area

The Ultimate Heartbreak Songs

Richest Teenagers in the World

10 Most Haunted Places in America

10 Best Places to Retire in Florida East Coast

Top 10 Places to See Before You Die

Top 8 Countries in the World Where Justice Prevails

10 Richest States in America

15 Wealthiest Countries in the World

Richest Singers in the World

Most Expensive Tasting Menu in New York City

Most Expensive Baby Items in the World

Most Expensive Hotel Suites in Vegas

Most Expensive Brunch in New York City

Most Expensive Beef Cuts in the World

25 Best Colleges to Get a Job

Top 10 US Supermarkets

The 25 Most Dangerous Cities in the World to Visit

Most Expensive Xbox Games

Top 11 Cities Where Billionaires Live

Top 10 Most Charitable Companies in America

Most Expensive Seafood in the World

The 10 Wildest Conspiracy Theories

The 10 Best Job Markets in the US

Top 10 Accounting Scandals of All Time

The 25 Biggest Cities in the World

Top 10 Best Paying Virtual Jobs

Most Expensive Leather Shoes in the World

Top 6 Things to Buy in March

The 10 Most Stressful Jobs in America – 2014 List

Top 10 Jobs for Introverted People

Top 10 Honeymoon Destinations in the World

Subscribe

Enter your email:

Delivered by FeedBurner

X

Thanks! An email with instructions is sent to !

Your email already exists in our database. Click here to go to your subscriptions

Insider Monkey returned 47.6% in its first year! Wondering How?

Download a complete edition of our newsletter for free!